There is no final "semaglutide ban" yet. What exists is an FDA proposal, published on 1 May 2026, not to put semaglutide, tirzepatide and liraglutide on the list of bulk ingredients that large outsourcing facilities (503B) may compound from. The comment period closed on 30 July 2026. As of 7 October 2026, FDA has published no final decision in the Federal Register.
By Alexandru Vieru · Independently researched · Updated 7 October 2026
Correction, 7 October 2026: earlier versions of this article said the comment period closed on 29 June and described the proposal as a proposed rule on a multi-year rulemaking timeline. FDA extended the deadline to 30 July, and the proposal is a notice on FDA's 503B bulks list, not a rule. Both are corrected below, and the timeline built on the wrong mechanism has been removed.
What FDA actually proposed
| Date | What happened | Source |
|---|---|---|
| 1 May 2026 | FDA notice: proposes not to include semaglutide, tirzepatide or liraglutide on the 503B bulks list (docket FDA-2018-N-3240) | Federal Register 2026-08552 |
| 26 Jun 2026 | Comment period extended | Federal Register 2026-12937 |
| 30 Jul 2026 | Comment period closed | Federal Register 2026-12937 |
| 7 Oct 2026 | No final decision published in the docket | Federal Register docket search, 7 Oct 2026 |
The 503B bulks list decides which active ingredients outsourcing facilities, the large compounders that make drugs in volume without patient-specific prescriptions, may use. FDA's proposal says there is no clinical need for them to compound these three GLP-1s from bulk now that the branded products are no longer in shortage. You can read FDA's announcement of the proposal.
Two things follow from that:
- It is a list decision, not a new law. FDA doesn't have to go through full notice-and-comment rulemaking to finalise it; it can announce its decision in a later notice. Nobody outside FDA knows when that will be.
- It is about 503B outsourcing facilities. It doesn't directly decide what an ordinary state-licensed (503A) pharmacy may compound for an individual patient.
503A vs 503B: the two kinds of compounder
| 503A pharmacy | 503B outsourcing facility | |
|---|---|---|
| Overseen by | State board of pharmacy | Registered with FDA |
| Prescription | Patient-specific prescription required | Can compound without one |
| Scale | Individual patients | Large batches |
| When it may use bulk semaglutide or tirzepatide | For an identified patient, but not regularly or in large amounts for "essentially copies" of an approved drug | Only if the drug is in shortage or on the 503B bulks list; FDA has proposed not listing them |
Most online clinics fill prescriptions through 503A pharmacies, which is why the 503B proposal hasn't stopped them.
What it means for 503A compounding, and why 503A isn't "safe"
Most online GLP-1 clinics fill prescriptions through 503A pharmacies, which compound for individual patients. That route isn't covered by the bulks-list proposal, but it isn't unrestricted either. A 503A pharmacy may not regularly compound "essentially copies" of a commercially available, FDA-approved drug.
FDA is enforcing that. On 18 September 2026 it sent a warning letter to Empower Pharmacy, a 503A pharmacy and one of the largest compounders of GLP-1s. The letter names tirzepatide with niacinamide and semaglutide with cyanocobalamin (vitamin B12), and says they "appear to be essentially copies of FDA-approved semaglutide and tirzepatide products." It also says the differences between those products and the approved drugs appear "pretextual."
That matters for patients because adding an ingredient such as B12 has been one of the common ways compounded GLP-1s were set apart from the branded drugs. The letter says FDA does not accept that as a difference by itself.
The safety picture FDA keeps citing
FDA's page on unapproved GLP-1 drugs used for weight loss, last updated 1 October 2026, says that as of 31 May 2026 it had received 990 adverse-event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. Reports are not proof that the drug caused the event, but the numbers are rising and FDA cites them in its enforcement.
FDA warning letters to clinics we track
Separately from pharmacies, FDA has sent warning letters to telehealth companies over how they market compounded GLP-1s. These are the clinics we rank that have an open letter on file, from our own records:
| Clinic | Letter date | Letter subject |
|---|---|---|
| Direct Meds | 9 Sep 2025 | Unlawful sale of unapproved and misbranded drugs (telehealth) |
| Zealthy | 9 Sep 2025 | Unlawful sale of unapproved and misbranded drugs (telehealth) |
| Remedy Meds | 9 Sep 2025 | Unlawful sale of unapproved and misbranded drugs (telehealth) |
| Ageless | 9 Sep 2025 | Unlawful sale of unapproved and misbranded drugs (telehealth) |
| SkinnyRx | 20 Feb 2026 | False and misleading claims, misbranded (telehealth) |
| Strut Health | 20 Feb 2026 | False and misleading claims, misbranded (telehealth) |
| MEDVi | 20 Feb 2026 | False and misleading claims, misbranded (telehealth) |
Our full list, including closeouts and the industry-wide waves, is on FDA warning letters. A letter is not a shutdown order, and each clinic's review explains what it was about.
What could happen next
We won't put a date on it, because FDA hasn't. The realistic outcomes:
- FDA finalises the proposal as written. Outsourcing facilities could no longer compound these three GLP-1s from bulk. Supply from 503B facilities would end; 503A compounding would continue under the "essentially copies" limits.
- FDA changes or delays the decision after reviewing the comments. Nothing changes for patients until it acts.
- Stricter 503A enforcement either way. The Empower letter shows FDA doesn't need the bulks-list decision to act against 503A products it considers copies.
What to do if you're on compounded semaglutide
- Your prescription isn't cancelled by any of this. Nothing final has happened to 503B, and 503A compounding continues.
- Ask your clinic which pharmacy fills your prescription and whether it's a 503A pharmacy or a 503B outsourcing facility. A clinic that can't say is a warning sign in itself.
- Be wary of "plus B12" or similar formulations marketed as different from Wegovy or Ozempic. FDA's September letter targets exactly that.
- Know the branded price before you need it. Novo Nordisk's self-pay price for Wegovy pens through NovoCare is now $199 a month for the first two fills of the starting doses, then $349 ($399 for Wegovy HD). See how much GLP-1 weight loss costs for brand and compounded prices side by side.
- Check the clinic. Our FDA warning letters page and each clinic's review show open letters.
FAQ
Is semaglutide banned in 2026? No. Branded semaglutide (Wegovy, Ozempic, Rybelsus) is FDA-approved and available. Compounded semaglutide is still being made. FDA has proposed keeping it off the 503B bulks list, but had not finalised that as of 7 October 2026.
When did the comment period close? 30 July 2026, after FDA extended the original 30 June deadline.
Does the proposal affect 503A pharmacies? Not directly. But 503A pharmacies are bound by the "essentially copies" rule, and FDA's September 2026 warning letter to Empower Pharmacy shows it is enforcing it.
Is compounded semaglutide safe? Compounded drugs aren't FDA-approved, so FDA hasn't reviewed their safety, effectiveness or quality. FDA has received 990 adverse-event reports for compounded semaglutide as of 31 May 2026. Talk to a clinician about the risks.
Sources: Federal Register 2026-08552 (1 May 2026) and 2026-12937 (26 June 2026), docket FDA-2018-N-3240, checked 7 October 2026; FDA warning letter to Empower Pharmacy, 18 September 2026; FDA, "FDA's concerns with unapproved GLP-1 drugs used for weight loss" (content current as of 1 October 2026); NovoCare Pharmacy Wegovy self-pay prices, read 7 October 2026. Clinic letters from our own records of FDA's warning-letter database. This is general information, not medical or legal advice.
